Blue Jet Healthcare Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹376 Cr +127.9% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
BJ

Blue Jet Healthcare Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Blue Jet Healthcare Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹165Cr
−20.7% YoY
−53.5% QoQ
Net profit
₹52Cr
−10.3% YoY
−42.9% QoQ
Margin
33%
0 pp YoY
−1 pp QoQ
Price₹596
Market cap₹11.1K Cr
P/E47.1

The short version

The company anticipates stable to growing order book momentum with strong medium to long-term visibility fueled by global customer commitments. The company expects stable to improving revenues in the contrast media segment over the next 12-18 months, driven by commercial-scale launch of new iodinated intermediates and growth in the NCE molecule for MRI.

From Blue Jet Healthcare Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company anticipates stable to growing order book momentum with strong medium to long-term visibility fueled by global customer commitments.
  • Capacity expansions at Vizag (103 acres) and backward integration facility at Mahad are on track, with Phase-I at Vizag targeting completion by FY '28, adding 1,000 KL capacity over 2-3 years.
  • Growth in the cardiovascular drug segment (notably Bempedoic Acid) is expected to continue, with triple-digit percentage growth reported and approvals in new markets like Japan expanding opportunities.
  • Contrast media shipments faced transit delays but volumes and revenues are expected to normalize and sustain at FY '23 levels over the next 12-18 months.

2 more points from Blue Jet Healthcare Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Blue Jet Healthcare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Blue Jet Healthcare is expanding capacity with a major CAPEX plan including a new 103-acre site in Vizag.
  • Phase-I of Vizag project, with an approximate CAPEX of Rs. 1,000 crores, will have 4 blocks: 2 for Contrast Media, 1 for high-intensity Sweetener, and 1 multipurpose block including peptide fragments for GLPs; expected completion by FY '28.
  • Backward integration facility at Mahad with a CAPEX of about Rs. 300 crores (increased from Rs. 250 crores due to automation); commissioning expected by H2 FY '26.
  • A state-of-the-art R&D center is planned in Hyderabad at a cost of Rs. 40 crores to enhance capabilities including peptides, GLP1 intermediates, and biocatalysts.

2 more points from Blue Jet Healthcare Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Blue Jet Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The order book visibility for contrast media (marketed product) remains stable as per management comments.
  • The order book for intermediates, specifically for the NCE molecule, is noted to be encouraging.
  • Commercial scale supply for iodinated intermediates expected to commence in Q4 of the financial year.
  • Management emphasized a long-term view on capacity build-up aligned with orders, indicating visibility over 5 years, though ramp-up timing may vary by 12-18 months.
  • Customer off-take and schedules cause some quarter-on-quarter volatility but overall order book remains solid.
  • Growth prospects for Pharma Intermediate segment, including Bempedoic Acid and other chronic disease molecules, supported by good order visibility and new approvals.

2 more points from Blue Jet Healthcare Ltd's call on order book

Create a free account to keep reading this call

Blue Jet Healthcare Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Blue Jet Healthcare Ltd Q2 FY26 results — key figures

Blue Jet Healthcare Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue165208-20.7%355-53.5%
Operating profit (EBITDA)5569-20.3%121-54.5%
Operating margin33%33%0 pp34%-1 pp
Profit before tax6977-10.4%123-43.9%
Net profit (PAT)5258-10.3%91-42.9%
EPS (₹)3.013.36-10.4%5.26-42.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹376 Cr, net profit ₹103 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Blue Jet Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Blue Jet Healthcare Ltd Q2 FY26 results?

The company anticipates stable to growing order book momentum with strong medium to long-term visibility fueled by global customer commitments. The company expects stable to improving revenues in the contrast media segment over the next 12-18 months, driven by commercial-scale launch of new iodinated intermediates and growth in the NCE molecule for MRI.

What is Blue Jet Healthcare Ltd share price analysis?

Blue Jet Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 47.1 with a market cap of ₹11,063 Cr. Investors should review the full earnings analysis for detailed insights.

Is Blue Jet Healthcare Ltd planning capital expenditure?

Blue Jet Healthcare is expanding capacity with a major CAPEX plan including a new 103-acre site in Vizag.

Keep Blue Jet Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.